ABSTRACT
Adrenal Castleman's disease is rare. One case of left adrenal Castleman's disease, who underwent retroperitoneal laparoscopic left adrenal gland and tumor resection. The postoperative pathological diagnosis was adrenal Castleman's disease (transparent vascular type), and no tumor recurrence was found after 2 years of follow-up.
ABSTRACT
<p><b>BACKGROUND</b>To study the relationship between human thymosin β4 (Tβ4 )expression and biological factors regarding invasion, metastasis and prognosis of human non-small cell lung cancer (NSCLC).</p><p><b>METHODS</b>Tβ4 expression was detected in samples of 76 paraffin-embedded specimens with the neighboring noncancerous tissue using anti-Tβ4 IgY antibody (primary antibody) by immunohistochemical staining. The relationship between Tβ4 expression and the clinicopthological factors was analyzed by Chi-square test, multivariate analysis and Kaplan-Meier method.</p><p><b>RESULTS</b>In immunoreactive cells, staining was mainly located in cytoplasma. Human Tβ4 expression was high positive in lung cancer tissues (76.3%, 58/76) while low positive in normal lung tissues. Tβ4 expression was positively associated with TNM stage (r=0.239, P=0.032), lymphatic metastasis (r=0.243, P=0.029) and venous metastasis (r=0.224, P=0.045).A negative correlation was found between Tβ4 expression and cell differentiation (r=-0.368, P=0.002). Patients with high Tβ4 expression had a worse prognosis than those with low Tβ4 expression (P < 0.05)</p><p><b>CONCLUSIONS</b>Lung cancer has overexpression of Tβ4, which is closely related to TNM stages, cell differentiation, metastasis of the cancer and prognosis of the patients with lung cancer. Detection of Tβ4 expression in lung cancer tissues might be helpful to predict prognosis of patients with lung cancer.</p>
ABSTRACT
Drug release from alpha-TCP cement containing tetracycline hydrochloride (TTCH) was studied in vitro. Results from X-ray diffraction study indicated that TTCH did not prevent the hydration of alpha-TCP. In vitro drug release study showed that TTCH release could sustain over 1200 h, and the release was controlled by two mechanisms: (1) diffusion of free TTCH molecules through the porous cement (square-root-of-time kinetics); (2) dissociation of TTCH from the apatite-TTCH complex (zero-order kinetics). The mechanism controlling release would changed with the variety of the antibiotic content of cement pellets, as a result of TTCH adsorption and bonding on calcium phosphates. The first mechanism was predominantly for low concentration system TTCH-loaded apatite cement systems at the initial release period, and for high concentration TTCH-loaded apatite cement systems. As for low concentration TTCH-loaded apatite cement systems at later release stage, drug release was controlled by the coupling of the two mechanisms.